Finanzwire Finanzwire
Basculer en Français
9629 Companies
191456 Keywords
122915 Articles
102031 Press releases
Headlines Articles Press releases NLS Pharmaceutics AG Remove
  1. Home
  2. Companies
  3. NLS Pharmaceutics AG
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 08/28/2023 at 13:30, 2 years 4 months ago

    NLS Pharmaceutics CEO Issues Letter to Shareholders

    Logo of NLS Pharmaceutics AG
  • PRESS RELEASE

    published on 05/02/2023 at 14:45, 2 years 8 months ago

    NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

    Logo of NLS Pharmaceutics AG
  • PRESS RELEASE

    published on 03/27/2023 at 14:30, 2 years 9 months ago

    NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2

    Logo of NLS Pharmaceutics AG
  • PRESS RELEASE

    published on 01/23/2023 at 14:30, 2 years 11 months ago

    NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity

    Logo of NLS Pharmaceutics AG
  • PRESS RELEASE

    published on 01/12/2023 at 14:30, 2 years 11 months ago

    NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds

    Logo of NLS Pharmaceutics AG
Accesswire
  • Published on 01/10/2026 at 05:10, 1 day 14 hours ago

    Sekur Private Data Ltd. Announces Non-Brokered Private Placement

  • Published on 01/10/2026 at 00:45, 1 day 19 hours ago

    Digi Power X Announces Entry into Settlement Agreement

  • Published on 01/09/2026 at 23:30, 1 day 20 hours ago

    Sun Peak Metals Grants Stock Options

  • Published on 01/09/2026 at 23:30, 1 day 20 hours ago

    Matador Technologies Announces Grant of Restricted Share Units to Management Team

  • Published on 01/09/2026 at 23:10, 1 day 20 hours ago

    Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction

View all ACCESSWIRE
EQS Group
  • Published on 01/10/2026 at 21:25, 22 hours 36 minutes ago

    CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh

  • Published on 01/10/2026 at 13:05, 1 day 6 hours ago

    SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation

  • Published on 01/09/2026 at 21:55, 1 day 22 hours ago

    Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)

  • Published on 01/09/2026 at 18:36, 2 days 1 hour ago

    Fuller, Smith & Turner PLC: Transaction in own shares

  • Published on 01/09/2026 at 18:19, 2 days 1 hour ago

    EQS-Adhoc: BayWa AG: Change in the Board of Management of BayWa AG

View all EQS
Les Echos
  • Published on 01/09/2026 at 18:30, 2 days 1 hour ago

    H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm

  • Published on 01/09/2026 at 17:45, 2 days 2 hours ago

    January 2026

  • Published on 01/09/2026 at 17:45, 2 days 2 hours ago

    MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

  • Published on 01/09/2026 at 17:42, 2 days 2 hours ago

    Aéroports de Paris SA - Shares and voting rights as of 31 December 2025

  • Published on 01/08/2026 at 21:00, 2 days 23 hours ago

    Biannual report on SEB S.A.’S liquidity agreement

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy